Press Releases September 2, 2026 08:00 AM

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

Beyond Air to Present at the 2026 Cantor Global Healthcare Conference

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
XAIR

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company specializing in nitric oxide therapies, announced its management will participate in the 2026 Cantor Global Healthcare Conference. The company will hold a fireside chat and offer a webcast to discuss its latest developments, including its FDA-approved LungFit PH system for neonatal respiratory failure.

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
XAIR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Beyond Air focuses on medical devices and biopharmaceuticals using nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors.
  • The company’s LungFit PH system has received FDA approval and CE Mark for treating term and near-term neonates with hypoxic respiratory failure.
  • Management’s participation in a major healthcare conference provides an opportunity to increase investor awareness and share updates.

GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, which is being held at the Waldorf Astoria New York, New York on September 9-11, 2026.

Fireside Chat Details:
Date: Thursday, September 10th
Time: 3:55 PM EDT 
Webcast Link: A live webcast of the fireside chat will be available on the Events section of the Company’s website, https://www.beyondair.net/news-events/events. Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days.

If you are interested in requesting a one-on-one meeting at the conference, please contact your Cantor representative to schedule accordingly.

About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.

CONTACTS:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577


Risks

  • Market reception depends on clinical outcomes and adoption of LungFit PH and future products, which remain subject to regulatory and commercial challenges.
  • Competition within the medical device and biopharmaceutical sectors could impact growth potential and market share.
  • Technology development and market penetration timelines may vary, adding uncertainty to future revenue projections.

More from Press Releases

Reborn Coffee Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements Sep 3, 2026 HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy Sep 3, 2026 LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China Sep 3, 2026 Ming Shing Group Holdings Limited Announces Closing of the Acquisition of Meals Through Seasons Limited and Issuance of Consideration Shares and Unsecured Convertible Promissory Notes Sep 2, 2026 Diversified Announces Accretive Acquisition of Birch Sep 2, 2026